Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation

Immunological Reviews

Volumn 270, Issue 1, 2016, Pages 132-151

  Igawa, Tomoyuki ^a   Haraya, Kenta ^b   Hattori, Kunihiro ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b Chugai Pharmabody Research Pte Ltd   (Singapore)

Author keywords

FcRn; Fc RIIb; pH dependent antigen binding antibody; Sweeping antibody

Indexed keywords

ANTIGEN; FC RECEPTOR; INTERLEUKIN 6; MONOCLONAL ANTIBODY; SWEEPING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; NEUTRALIZING ANTIBODY; PROTEIN BINDING;

AMINO ACID SUBSTITUTION; ANTIBODY ENGINEERING; ANTIGEN BINDING; BINDING AFFINITY; CELL SURFACE; CIRCULATION; COMPLEMENTARITY DETERMINING REGION; CONFORMATIONAL TRANSITION; DISSOCIATION; ENDOCYTOSIS; ENDOSOME; HEAVY CHAIN; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MACACA FASCICULARIS; NONHUMAN; PHAGE DISPLAY; PLASMA CLEARANCE; PRIORITY JOURNAL; REVIEW; ANIMAL; ANTIBODY AFFINITY; ANTIBODY PRODUCTION; BLOOD; CHEMISTRY; DRUG DEVELOPMENT; GENETIC ENGINEERING; GENETICS; IMMUNOLOGY; METABOLISM; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODY AFFINITY; ANTIBODY FORMATION; ANTIGENS; DRUG DISCOVERY; GENETIC ENGINEERING; HUMANS; PROTEIN BINDING; RECEPTORS, FC;

EID: 84957702575     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12392     Document Type: Review

References (96)

1. Elvin JG, Couston RG, van der Walle CF. Therapeutic antibodies: market considerations, disease targets and bioprocessing. Int J Pharm 2013;440:83-98.
2. Igawa T, Tsunoda H, Kuramochi T, Sampei Z, Ishii S, Hattori K. Engineering the variable region of therapeutic IgG antibodies. mAbs 2011;3:243-252.
3. Vincent KJ, Zurini M. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates. Biotechnol J 2012;7:1444-1450.
4. Bradbury AR, Sidhu S, Dubel S, McCafferty J. Beyond natural antibodies: the power of in vitro display technologies. Nat Biotechnol 2011;29:245-254.
5. Rathanaswami P, Roalstad S, Roskos L, Su QJ, Lackie S, Babcook J. Demonstration of an in vivo generated sub-picomolar affinity fully human monoclonal antibody to interleukin-8. Biochem Biophys Res Commun 2005;334:1004-1013.
6. Xiao JJ, et al. Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9 m and hepcidin in cynomolgus monkeys. AAPS J 2010;12:646-657.
7. Haringman JJ, et al. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:2387-2392.
8. Martin PL, et al. Reviews preclinical safety and immune-modulating effects of therapeutic monoclonal antibodies to interleukin-6 and tumor necrosis factor-alpha in cynomolgus macaques. J Immunotoxicol 2005;1:131-139.
9. Byrd JC, et al. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 2007;13:4448-4455.
10. Jayson GC, et al. Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer. Eur J Cancer 2005;41:555-563.
11. Finkelman FD, et al. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J Immunol 1993;151:1235-1244.
12. Feinberg H, Torgersen D, Drickamer K, Weis WI. Mechanism of pH-dependent N-acetylgalactosamine binding by a functional mimic of the hepatocyte asialoglycoprotein receptor. J Biol Chem 2000;275:35176-35184.
13. Lennartz MR, Wileman TE, Stahl PD. Isolation and characterization of a mannose-specific endocytosis receptor from rabbit alveolar macrophages. Biochem J 1987;245:705-711.
14. Yamamoto T, Chen HC, Guigard E, Kay CM, Ryan RO. Molecular studies of pH-dependent ligand interactions with the low-density lipoprotein receptor. Biochemistry 2008;47:11647-11652.
15. Igawa T, et al. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol 2010;28:1203-1207.
16. Igawa T, et al. Engineered monoclonal antibody with novel antigen-sweeping activity in vivo. PLoS ONE 2013;8:e63236.
17. Igawa T, Mimoto F, Hattori K. pH-dependent antigen-binding antibodies as a novel therapeutic modality. Biochim Biophys Acta 2014;1844:1943-1950.
18. Iwayanagi Y, et al. Inhibitory FcgammaRIIb-mediated soluble antigen clearance from plasma by a pH-dependent antigen-binding antibody and its enhancement by Fc engineering. J Immunol 2015;195:3198-3205.
19. Weber J, et al. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J Clin Oncol 1993;11:499-506.
20. Greischel A, Zahn G. Pharmacokinetics of recombinant human tumor necrosis factor alpha in rhesus monkeys after intravenous administration. J Pharmacol Exp Ther 1989;251:358-361.
21. Eppler SM, et al. A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther 2002;72:20-32.
22. Wang W, et al. Mechanistic pharmacokinetic/target engagement/pharmacodynamic (PK/TE/PD) modeling in deciphering interplay between a monoclonal antibody and its soluble target in cynomolgus monkeys. AAPS J 2014;16:129-139.
23. Miyoshi I, et al. Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer's disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study. Int J Clin Pharmacol Ther 2013;51:911-923.
24. Mistry P, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single-dose antiinterleukin- 18 mAb GSK1070806 in healthy and obese subjects. Int J Clin Pharmacol Ther 2014;52:867-879.
25. Russell DW, Schneider WJ, Yamamoto T, Luskey KL, Brown MS, Goldstein JL. Domain map of the LDL receptor: sequence homology with the epidermal growth factor precursor. Cell 1984;37:577-585.
26. Rudenko G, et al. Structure of the LDL receptor extracellular domain at endosomal pH. Science 2002;298:2353-2358.
27. Lee DA, Goodfellow JM. The pH-induced release of iron from transferrin investigated with a continuum electrostatic model. Biophys J 1998;74:2747-2759.
28. Geuze HJ, Slot JW, Strous GJ, Lodish HF, Schwartz AL. Intracellular site of asialoglycoprotein receptor-ligand uncoupling: double-label immunoelectron microscopy during receptor-mediated endocytosis. Cell 1983;32:277-287.
29. Chaparro-Riggers J, et al. Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9. J Biol Chem 2012;287:11090-11097.
30. Zhang L, et al. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes. Int J Biol Sci 2012;8:310-327.
31. Chan JC, et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci USA 2009;106:9820-9825.
32. Henne KR, et al. Anti-PCSK9 antibody pharmacokinetics and low-density lipoprotein-cholesterol pharmacodynamics in nonhuman primates are antigen affinity-dependent and exhibit limited sensitivity to neonatal Fc receptor-binding enhancement. J Pharmacol Exp Ther 2015;353:119-131.
33. Devanaboyina SC, et al. The effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics. mAbs 2013;5:851-859.
34. Lammerts van Bueren JJ, et al. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res 2006;66:7630-7638.
35. Okimura K, et al. Characterization of ASKP1240, a fully human antibody targeting human CD40 with potent immunosuppressive effects. Am J Transplant 2014;14:1290-1299.
36. Cosson VF, Ng VW, Lehle M, Lum BL. Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer. Cancer Chemother Pharmacol 2014;73:737-747.
37. Popov S, Hubbard JG, Kim J, Ober B, Ghetie V, Ward ES. The stoichiometry and affinity of the interaction of murine Fc fragments with the MHC class I-related receptor, FcRn. Mol Immunol 1996;33:521-530.
38. Chaudhury C, Brooks CL, Carter DC, Robinson JM, Anderson CL. Albumin binding to FcRn: distinct from the FcRn-IgG interaction. Biochemistry 2006;45:4983-4990.
39. Kuo TT, et al. Neonatal Fc receptor: from immunity to therapeutics. J Clin Immunol 2010;30:777-789.
40. George JN, Saucerman S. Platelet IgG, IgA, IgM, and albumin: correlation of platelet and plasma concentrations in normal subjects and in patients with ITP or dysproteinemia. Blood 1988;72:362-365.
41. Praetor A, Ellinger I, Hunziker W. Intracellular traffic of the MHC class I-like IgG Fc receptor, FcRn, expressed in epithelial MDCK cells. J Cell Sci 1999;112(Pt 14):2291-2299.
42. Cooper PR, et al. The contribution of cell surface FcRn in monoclonal antibody serum uptake from the intestine in suckling rat pups. Front Pharmacol 2014;5:225.
43. Nixon AE, et al. Fully human monoclonal antibody inhibitors of the neonatal fc receptor reduce circulating IgG in non-human primates. Front Immunol 2015;6:176.
44. Yeung YA, et al. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol 2009;182:7663-7671.
45. Bruhns P, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009;113:3716-3725.
46. van Sorge NM, van der Pol WL, van de Winkel JG. FcgammaR polymorphisms: implications for function, disease susceptibility and immunotherapy. Tissue Antigens 2003;61:189-202.
47. Mimoto F, et al. Novel asymmetrically engineered antibody Fc variant with superior FcgammaR binding affinity and specificity compared with afucosylated Fc variant. mAbs 2013;5:229-236.
48. Gillis C, Gouel-Cheron A, Jonsson F, Bruhns P. Contribution of Human FcgammaRs to Disease with Evidence from Human Polymorphisms and Transgenic Animal Studies. Front Immunol 2014;5:254.
49. Takai T. Roles of Fc receptors in autoimmunity. Nat Rev Immunol 2002;2:580-592.
50. Ganesan LP, et al. FcgammaRIIb on liver sinusoidal endothelium clears small immune complexes. J Immunol 2012;189:4981-4988.
51. Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 2012;119:5640-5649.
52. Mimoto F, et al. Engineered antibody Fc variant with selectively enhanced FcgammaRIIb binding over both FcgammaRIIa(R131) and FcgammaRIIa(H131). PEDS 2013;26:589-598.
53. Hironiwa N, et al. Calcium-dependent antigen binding as a novel modality for antibody recycling by endosomal antigen dissociation. mAbs 2016;8:65-73.
54. Johansson AG, Lovdal T, Magnusson KE, Berg T, Skogh T. Liver cell uptake and degradation of soluble immunoglobulin G immune complexes in vivo and in vitro in rats. Hepatology 1996;24:169-175.
55. Bonvin P, et al. De novo isolation of antibodies with pH-dependent binding properties. mAbs 2015;7:294-302.
56. Murtaugh ML, Fanning SW, Sharma TM, Terry AM, Horn JR. A combinatorial histidine scanning library approach to engineer highly pH-dependent protein switches. Protein Sci 2011;20:1619-1631.
57. Schroter C, et al. A generic approach to engineer antibody pH-switches using combinatorial histidine scanning libraries and yeast display. mAbs 2015;7:138-151.
58. Gerasimenko JV, Tepikin AV, Petersen OH, Gerasimenko OV. Calcium uptake via endocytosis with rapid release from acidifying endosomes. Curr Biol 1998;8:1335-1338.
59. Giragossian C, Clark T, Piche-Nicholas N, Bowman CJ. Neonatal Fc receptor and its role in the absorption, distribution, metabolism and excretion of immunoglobulin G-based biotherapeutics. Curr Drug Metab 2013;14:764-790.
60. Olafsen T. Fc engineering: serum half-life modulation through FcRn binding. Methods Mol Biol 2012;907:537-556.
61. Hinton PR, Xiong JM, Johlfs MG, Tang MT, Keller S, Tsurushita N. An engineered human IgG1 antibody with longer serum half-life. J Immunol 2006;176:346-356.
62. Dall'Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 2006;281:23514-23524.
63. Zalevsky J, et al. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 2010;28:157-159.
64. Deng R, et al. Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-[alpha] antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metabol Dispos 2010;38:600-605.
65. Oganesyan V, et al. Structural insights into neonatal Fc receptor-based recycling mechanisms. J Biol Chem 2014;289:7812-7824.
66. Zheng Y, et al. Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase I study. Clin Pharmacol Ther 2011;89:283-290.
67. Kurlander RJ, Ellison DM, Hall J. The blockade of Fc receptor-mediated clearance of immune complexes in vivo by a monoclonal antibody (2.4G2) directed against Fc receptors on murine leukocytes. J Immunol 1984;133:855-862.
68. Chu SY, et al. Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies. Mol Immunol 2008;45:3926-3933.
69. Smith P, DiLillo DJ, Bournazos S, Li F, Ravetch JV. Mouse model recapitulating human Fcgamma receptor structural and functional diversity. Proc Natl Acad Sci USA 2012;109:6181-6186.
70. Meyer T, et al. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost 2009;7:171-181.
71. Robles-Carrillo L, et al. Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice. J Immunol 2010;185:1577-1583.
72. Betts AM, et al. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J Pharmacol Exp Ther 2010;333:2-13.
73. Luu KT, Bergqvist S, Chen E, Hu-Lowe D, Kraynov E. A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition. J Pharmacol Exp Ther 2012;341:702-708.
74. Gibiansky L, Gibiansky E. Target-mediated drug disposition model: relationships with indirect response models and application to population PK-PD analysis. J Pharmacokinet Pharmacodyn 2009;36:341-351.
75. Pivot X, et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol 2013;14:962-970.
76. Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol 2007;63:548-561.
77. Reiss UM, et al. Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria. Pediatr Blood Cancer 2014;61:1544-1550.
78. Dmytrijuk A, Robie-Suh K, Cohen MH, Rieves D, Weiss K, Pazdur R. FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Oncologist 2008;13:993-1000.
79. Sissons JG, Liebowitch J, Amos N, Peters DK. Metabolism of the fifth component of complement, and its relation to metabolism of the third component, in patients with complement activation. J Clin Invest 1977;59:704-715.
80. Takano S, et al. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res 1996;56:2185-2190.
81. Schlachetzki F, Zhu C, Pardridge WM. Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier. J Neurochem 2002;81:203-206.
82. Lunnon K, Teeling JL, Tutt AL, Cragg MS, Glennie MJ, Perry VH. Systemic inflammation modulates Fc receptor expression on microglia during chronic neurodegeneration. J Immunol 2011;186:7215-7224.
83. Esfandi F, Mohammadzadeh Ghobadloo S, Basati G. Interleukin-6 level in patients with colorectal cancer. Cancer Lett 2006;244:76-78.
84. White ES, et al. Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin Cancer Res 2003;9:853-860.
85. Yotsumoto F, Oki E, Tokunaga E, Maehara Y, Kuroki M, Miyamoto S. HB-EGF orchestrates the complex signals involved in triple-negative and trastuzumab-resistant breast cancer. Int J Cancer 2010;127:2707-2717.
86. Ziolkowska M, et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum 2002;46:1744-1753.
87. Huang SK, et al. IL-13 expression at the sites of allergen challenge in patients with asthma. J Immunol 1995;155:2688-2694.
88. Dudal S, et al. Integrated pharmacokinetic, pharmacodynamic and immunogenicity profiling of an anti-CCL21 monoclonal antibody in cynomolgus monkeys. mAbs 2015;7:829-837.
89. Robbie GJ, et al. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother 2013;57:6147-6153.
90. Lippow SM, Wittrup KD, Tidor B. Computational design of antibody-affinity improvement beyond in vivo maturation. Nat Biotechnol 2007;25:1171-1176.
91. Marvin JS, Lowman HB. Redesigning an antibody fragment for faster association with its antigen. Biochemistry 2003;42:7077-7083.
92. Katakura Y, et al. A practical kinetic model for efficient isolation of useful antibodies from phage display libraries. J Mol Catalysis B Enzym 2004;28:191-200.
93. Montero-Julian FA, Klein B, Gautherot E, Brailly H. Pharmacokinetic study of anti-interleukin-6 (IL-6) therapy with monoclonal antibodies: enhancement of IL-6 clearance by cocktails of anti-IL-6 antibodies. Blood 1995;85:917-924.
94. Mortensen DL, et al. Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies. mAbs 2012;4:724-731.
95. Datta-Mannan A, et al. FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys. Drug Metabol Dispos 2012;40:1545-1555.
96. Igawa T, et al. Reduced elimination of IgG antibodies by engineering the variable region. PEDS 2010;23:385-392.